Processa PharmaceuticalsPCSA +9.64%28 5-Year ROIIC % is 112.68 as of Dec. 2025. GuruFocus rates PCSA with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 1,173 Biotechnology companies, Processa Pharmaceuticals ranks better than 84.65% on this metric.
5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year.
Processa Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2025 was 112.68%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Processa Pharmaceuticals's 5-Year ROIIC % or its related term are showing as below:
PCSA's 5-Year ROIIC % is ranked better than 84.65% of 1173
companies
in the Biotechnology industry
Industry Median: -11.04
vs PCSA: 112.68
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Processa Pharmaceuticals 5-Year ROIIC % Related Terms
Processa Pharmaceuticals 5-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCSA vs ELAB, MBIO, DRMA: 5-Year ROIIC % Comparison
For the Biotechnology subindustry, Processa Pharmaceuticals's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Processa Pharmaceuticals 5-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Processa Pharmaceuticals's 5-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Processa Pharmaceuticals's 5-Year ROIIC % falls into.
Processa Pharmaceuticals's 5-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
5-Year ROIIC %
=
5-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
5-Year Incremental Invested Capital**
=
( -13.989 (Dec. 2025) - -6.0192387 (Dec. 2020) )
/
( 2.143 (Dec. 2025) - 9.216 (Dec. 2020) )
=
-7.9697613
/
-7.073
=
112.68%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Processa Pharmaceuticals (PCSA) has a 5-Year ROIIC % of 112.68 as of Dec. 2025. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Processa Pharmaceuticals and its competitors. According to the industry distribution chart, Processa Pharmaceuticals ranks #180 out of 1173 companies in the Biotechnology industry, placing it in the top 15.3%.
Is Processa Pharmaceuticals' 5-Year ROIIC % too high?
Processa Pharmaceuticals' current 5-Year ROIIC % is 112.68. Based on the distribution chart, Processa Pharmaceuticals ranks #180 out of 1173 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Processa Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Processa Pharmaceuticals' 5-Year ROIIC % compare to ELAB and MBIO?
According to the Biotechnology industry distribution chart, Processa Pharmaceuticals ranks #180 out of 1173 companies for 5-Year ROIIC %. This places Processa Pharmaceuticals in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year ROIIC % for a Biotechnology company?
A good 5-Year ROIIC % depends on the Biotechnology industry context. However, 5-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year ROIIC % mean?
A high 5-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 5-Year ROIIC % measures the change in earnings as a percentage of change in investment over 5-year. View historical data on Processa Pharmaceuticals and its competitors. Processa Pharmaceuticals's current 5-Year ROIIC % is 112.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Processa Pharmaceuticals stock overvalued right now?
Processa Pharmaceuticals (PCSA) has a current 5-Year ROIIC % of 112.68. The current 5-Year ROIIC % is 112.68. Processa Pharmaceuticals' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year ROIIC % calculated?
5-Year ROIIC % is calculated from a company's financial statements. For Processa Pharmaceuticals (PCSA), the current 5-Year ROIIC % is 112.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The four NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS11T, also referred to as NGC-Iri, is an analog of SN38, and PCS11T, PCS12852, and PCS499.
28GF Score
Get the complete analysis for PCSA
5-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCSA has been successfully added to your 
